AmMax is developing first-in-class or best-in-class therapeutics targeting a range of oncology diseases with significant unmet needs . Clinical trials are needed to assess the efficacy and safety of these experimental therapies.
AmMax is executing a multi-center, global Phase 2 clinical study program to assess the efficacy and safety of AMB-05X in patients with tenosynovial giant cell tumor (TGCT).
Study Title: A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor
AmMax has completed the following study in patients with tenosynovial giant cell tumor (TGCT)
Study Title: An adaptive, multicenter, open-label study to evaluate the safety, efficacy, and pharmacokinetics of intra-articular AMB-05X injection in subjects with tenosynovial giant cell tumor of the knee.
If you are interested in participating in the trial or have questions, please feel free to contact us at email@example.com.